Eisai reveals Lorcaserin Bloom-DM Phase 3 trial results
The Bloom-DM study evaluated obese and overweight patients with type 2 diabetes who were randomised to Lorcaserin 10mg BID, Lorcaserin 10mg dosed once daily (QD) or placebo. The
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic and autoimmune diseases. Antigen Express said that the proprietary vaccine being